All In MedTech

Device Trial Radar · NCT04246268

Assessment of the INVOcell Intravaginal Culture System

Assessment of the INVOcell Intravaginal Culture System During 5-day (120 Hours) Vaginal Incubation

Last checked: Nov 20, 2026Latest source record: Jul 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

180

Planned (sponsor's estimate)

Start

Oct 2020

Primary completion

Jul 2021

Study completion Mar 2022

Sponsor

Lead sponsor
INVO Bioscience, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Ferring Pharmaceuticals
First posted
Jan 29, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 37 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The INVOcell intravaginal culture system is a prescription device intended for preparing, holding, and transferring human gametes or embryos during intravaginal in vitro fertilization or intravaginal culture procedures. The original (FG-002) INVOcell culture system was FDA cleared through De Novo application (DEN150008). The purpose of this study is to evaluate the INVO Bioscience modified INVOcell system, comprised of the INVOcell Intravaginal Culture Device and Retention Device, in terms of the following: 2.1 Effectiveness of achieving fertilization, implantation, embryo development, clinical pregnancy, and live birth after 5-days of continuous vaginal incubation. 2.2 The comfort and retention of the INVOcell device and retention system intravaginally.

Conditions

  • Infertility

Interventions

  • INVOcellDevice

    Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Pregnancy RateTime frame: at 7 weeks of gestation

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Piedmont Reproductive Endocrinology Group

    Greenville, South Carolina

  • Piedmont Reproductive Endocrinology Group

    West Columbia, South Carolina

  • Fertility Center of San Antonio

    San Antonio, Texas

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.